# The Moderating Role of Baseline Oxytocin on Its Psychotherapy-facilitating Effects Among Patients With Eating Disorders

> **NCT05865288** · PHASE1 · UNKNOWN · sponsor: **Shalvata Mental Health Center** · enrollment: 90 (estimated)

## Conditions studied

- Eating Disorders

## Interventions

- **DRUG:** Oxytocin nasal spray

## Key facts

- **NCT ID:** NCT05865288
- **Lead sponsor:** Shalvata Mental Health Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-06-30
- **Primary completion:** 2024-04-30
- **Final completion:** 2025-04-30
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2023-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05865288

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05865288, "The Moderating Role of Baseline Oxytocin on Its Psychotherapy-facilitating Effects Among Patients With Eating Disorders". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05865288. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*